| Attribute |
Value |
| 52 Week Change |
-0.033707857 |
| Address1 |
62 Lygon Street |
| Address2 |
Level 3 |
| All Time High |
50.82 |
| All Time Low |
3.496 |
| Ask |
5.5 |
| Ask Size |
2 |
| Average Daily Volume10 Day |
18,530 |
| Average Daily Volume3 Month |
30,486 |
| Average Volume |
30,486 |
| Average Volume10Days |
18,530 |
| Beta |
0.795 |
| Bid |
3.09 |
| Bid Size |
2 |
| Book Value |
3.123 |
| City |
Carlton |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Country |
Australia |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
4.225 |
| Current Ratio |
3.01 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,782,777,600 |
| Day High |
4.3 |
| Day Low |
4.2 |
| Display Name |
Radiopharm Theranostics |
| Ebitda |
-39,179,988 |
| Ebitda Margins |
-2.40687 |
| Enterprise To Ebitda |
-0.369 |
| Enterprise To Revenue |
0.887 |
| Enterprise Value |
14,444,515 |
| Eps Forward |
-2.587254 |
| Eps Trailing Twelve Months |
-3.64 |
| Esg Populated |
0 |
| Exchange |
NCM |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fax |
61 3 9822 7735 |
| Fifty Day Average |
4.39422 |
| Fifty Day Average Change |
-0.16921997 |
| Fifty Day Average Change Percent |
-0.038509674 |
| Fifty Two Week Change Percent |
-3.3707857 |
| Fifty Two Week High |
16.25 |
| Fifty Two Week High Change |
-12.025 |
| Fifty Two Week High Change Percent |
-0.73999995 |
| Fifty Two Week Low |
3.62 |
| Fifty Two Week Low Change |
0.605 |
| Fifty Two Week Low Change Percent |
0.16712709 |
| Fifty Two Week Range |
3.62 - 16.25 |
| Financial Currency |
AUD |
| First Trade Date Milliseconds |
1,733,409,000,000 |
| Float Shares |
8,291,576 |
| Forward Eps |
-2.587254 |
| Forward P E |
-1.6330054 |
| Free Cashflow |
-20,874,536 |
| Full Exchange Name |
NasdaqCM |
| Full Time Employees |
14 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
-1.36508 |
| Gross Profits |
-22,221,420 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.0 |
| Held Percent Institutions |
0.0254 |
| Implied Shares Outstanding |
7,883,165 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Ipo Expected Date |
2,024-11-27 |
| Language |
en-US |
| Last Fiscal Year End |
1,751,241,600 |
| Long Business Summary |
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia. |
| Long Name |
Radiopharm Theranostics Limited |
| Market |
us_market |
| Market Cap |
33,306,372 |
| Market State |
REGULAR |
| Max Age |
86,400 |
| Message Board Id |
finmb_1685428878 |
| Most Recent Quarter |
1,767,139,200 |
| Net Income To Common |
-46,582,476 |
| Next Fiscal Year End |
1,782,777,600 |
| Non Diluted Market Cap |
32,603,196 |
| Number Of Analyst Opinions |
6 |
| Open |
4.225 |
| Operating Cashflow |
-37,101,336 |
| Operating Margins |
-4.23751 |
| Payout Ratio |
0.0 |
| Phone |
61 3 9824 5254 |
| Previous Close |
4.3 |
| Price Hint |
4 |
| Price To Book |
1.3528658 |
| Price To Sales Trailing12 Months |
2.0460434 |
| Profit Margins |
-2.8616102 |
| Quick Ratio |
2.999 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
none |
| Region |
US |
| Regular Market Change |
-0.075000286 |
| Regular Market Change Percent |
-1.7543926 |
| Regular Market Day High |
4.3 |
| Regular Market Day Low |
4.2 |
| Regular Market Day Range |
4.2 - 4.3 |
| Regular Market Open |
4.225 |
| Regular Market Previous Close |
4.3 |
| Regular Market Price |
4.225 |
| Regular Market Time |
1,784,125,083 |
| Regular Market Volume |
13,457 |
| Return On Assets |
-0.28328 |
| Return On Equity |
-0.92096 |
| Revenue Growth |
1.545 |
| Revenue Per Share |
2.1 |
| Sand P52 Week Change |
0.2043345 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
7,883,165 |
| Shares Percent Shares Out |
0.007900001 |
| Shares Short |
62,568 |
| Shares Short Previous Month Date |
1,780,012,800 |
| Shares Short Prior Month |
50,928 |
| Short Name |
Radiopharm Theranostics Limited |
| Short Percent Of Float |
0.01 |
| Short Ratio |
2.51 |
| Source Interval |
15 |
| State |
VIC |
| Symbol |
RADX |
| Target High Price |
30.155354 |
| Target Low Price |
12.683695 |
| Target Mean Price |
17.06205 |
| Target Median Price |
15.377537 |
| Total Cash |
34,515,396 |
| Total Cash Per Share |
2.922 |
| Total Debt |
0 |
| Total Revenue |
16,278,428 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-3.64 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
4.909295 |
| Two Hundred Day Average Change |
-0.6842952 |
| Two Hundred Day Average Change Percent |
-0.13938767 |
| Type Disp |
Equity |
| Volume |
13,457 |
| Website |
https://www.radiopharmtheranostics.com |
| Zip |
3,053 |